Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Datteln – page 59

1 785 clinical trials in Datteln, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Datteln at a glance
1 785
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 785 trials in Datteln

Open in trial search

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Diabetic retinal oedema

Not yet recruiting

Efficacy and safety of intravitreal MK-8748 versus aflibercept in adults with diabetic macular edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Obesity+2

Not yet recruiting

Phase 3 Randomized Trial of Once‑Monthly PF‑08653944 to Reduce Breathing Events in Adults with Obstructive Sleep Apnea and Overweight/Obesity Using a PAP Machine

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide
  • Sponsor:Pfizer Inc.

Narcolepsy

Not yet recruiting

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cutaneous sarcoidosis

Not yet recruiting

A Phase 2/3 Study of the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Lichen planus

Not yet recruiting

Efficacy and safety of GIA632 versus placebo in adults with moderate to severe cutaneous lichen planus

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Datteln

What the registry says about research in the country

01 Pediatric Oncology

Innovative research focusing on lymphoma and leukemia treatments in children and adolescents, including studies on B-cell lymphomas and acute myeloid leukemia. These trials aim to improve survival rates through targeted therapies and novel treatment combinations.

  • B-cell lymphoma treatments
  • Acute lymphoblastic leukemia
  • Germ cell tumors

Advanced protocols incorporating immunotherapy and chemotherapy combinations are being evaluated for optimal treatment outcomes.

02 Neurological Conditions

Studies addressing various neurological disorders, including multiple sclerosis and rare conditions like tuberous sclerosis complex. Research focuses on testing new therapeutic approaches and evaluating long-term neuropsychological outcomes.

  • Relapsing-remitting MS
  • Myelin disorders
  • Developmental disorders

Trials emphasize early intervention strategies and comparative treatment effectiveness.

03 Neonatal Care

Critical research in preterm infant care, focusing on respiratory distress syndrome and retinopathy of prematurity. Studies evaluate new treatment approaches and preventive measures for improved outcomes.

  • Surfactant administration
  • Retinopathy prevention
  • Respiratory support

Investigations aim to establish optimal protocols for premature infant care and development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.